MedTrace Logo

Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"

NCT00889967 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2017-01-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Ciprofloxacin for Inhalation in the treatment of patients with non-cystic fibrosis (CF) bronchiectasis.

Conditions

  • Non-Cystic Fibrosis Bronchiectasis

Interventions

DRUG

Ciprofloxacin for Inhalation

100 mg once daily by inhalation for 28 days

DRUG

Ciprofloxacin for Inhalation

150 mg once daily by inhalation for 28 days

DRUG

Placebo

Placebo once daily by inhalation for 28 days

Sponsors & Collaborators

  • Aradigm Corporation

    lead INDUSTRY

Principal Investigators

  • Paul Bruinenberg, MBChB, MBA · Aradigm Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-04-30
Completion
2011-06-30

Countries

  • United States
  • Canada
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00889967 on ClinicalTrials.gov